Developer docs
API playgroundTry for free, no card

Search company profiles

Corolabs

Full company profile

uuid002xu5t

Namestring
Corolabs
Websiteurl
corolabs.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Corolabs is a private, for-profit medical device / drug-delivery company headquartered in Migdal HaEmek, Israel. Per its firmographic description, the company develops proprietary inhalation systems specifically engineered to deliver medications to the alveoli — the deep gas-exchange regions of the lung — positioning it in the targeted pulmonary drug-delivery niche rather than conventional upper-airway or systemic inhalation therapy.

The company is founder-led: Asaf Weinberger is listed as Founder & CEO. No additional management, scientific advisors, board members, headcount, funding rounds, or strategic investors are disclosed in the available source material. There is no evidence of named customers, commercial products in market, partnership agreements, regulatory submissions, clinical milestones, patents, or certifications. The only verifiable public web presence captured in the input data is a listing on HugeDomains offering the corolabs.com domain for sale at $11,395, with that listing representing the domain registrar's commerce page rather than any corporate activity by Corolabs.

Because the source data contains no revenue, pricing, GTM, or product-portfolio detail, the company's current commercial stage cannot be reliably established. What can be stated with confidence is the company's stated technical focus (alveolar-targeted inhalation delivery), its jurisdiction (Israel), its founder identity, and its private, for-profit status. Any further inference on funding stage, burn rate, or runway would exceed the evidence available.

Short descriptiontext

Corolabs is a private Israeli company developing proprietary inhalation systems engineered to deliver medications directly to the alveoli for targeted pulmonary drug delivery.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersMigdal Hameq, Israel
HQ citystring
Migdal Hameq
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
inhaled drug delivery, pulmonary therapeutics, alveolar drug delivery, inhalation medical devices, respiratory drug delivery
Industry2 codes
PRIMARYHLAHAIAJ
Nebulizers & Aerosol Drug Delivery Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Pulmonary Drug Delivery Devices
No data
Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Pricing details2 tiers
1Domain purchase - full payment
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Buy now for $11,395 with immediate ownership transfer upon purchase

hugedomains.com
2Domain purchase - payment plan
ModelOtherBilling cadenceMonthly
Notes

$474.79 per month for 24 months (total $11,394.96), 0% interest financing available

hugedomains.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Corolabs specializes in proprietary inhalation systems specifically designed to deliver medications to the alveoli. The company's offering centers on a targeted pulmonary drug-delivery device platform intended for therapeutic use cases requiring deep-lung (alveolar) deposition of medication.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

The source data does not contain information about Corolabs's actual products or services. The page is from HugeDomains.com selling the domain name "CoroLabs.com" for $11,395. No product or service portfolio for Corolabs is described in this source.

Product and service1 record
1Proprietary Inhalation System for Alveolar Drug Delivery
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Develops inhaled therapeutics such as Tyvaso DPI for pulmonary hypertension, operating device-plus-formulation inhaled programs analogous to where Corolabs' platform could be applied.

2Omron Healthcare
TypeBroad incumbent
Description

Established manufacturer of consumer and clinical nebulizers; relevant comparable for the inhalation device category, though Corolabs' alveolar-targeting technology would be more specialized.

TypeDirect peer
Description

Specialist manufacturer of nebulizers and aerosol drug delivery systems for respiratory care, including devices engineered for deep-lung deposition — directly comparable to Corolabs' inhalation systems focus.

TypeEmerging player
Description

Pursues inhaled formulations (e.g., ARIKAYCE) delivered to deep lung tissue using advanced nebulizer platforms — directly analogous alveolar-targeted strategy with a working drug-device combination.

TypeDirect peer
Description

Developer of vibrating mesh nebulizer technology used in acute care and home settings to deliver drugs deep into the lungs; comparable as a device-only inhalation delivery company targeting alveolar deposition.

TypeBroad incumbent
Description

Markets high-flow respiratory drug delivery systems; shares the respiratory drug-delivery category and serves overlapping hospital/clinical customers.

TypeBroad incumbent
Description

Large incumbent offering inhalation/nebulizer devices and ventilation solutions as part of a broader respiratory portfolio; overlaps with Corolabs on device-based drug delivery but covers a much wider product range.

8Civitas Therapeutics (acquired by Acorda)
TypeEmerging player
Description

Built an inhaled levodopa (ARCUS) platform targeting deep-lung delivery for Parkinson's; matches Corolabs' combination-product inhaled delivery thesis on a different therapeutic target.

TypeEmerging player
Description

Early-stage company working on inhaled therapeutics for pulmonary disease; relevant as a similarly sized emerging inhaled-drug-delivery peer in the same category.

TypeEmerging player
Description

Developed a soft-mist inhaled insulin/biologics platform; comparable as a focused drug-device company pursuing deep-lung delivery rather than competing across broad respiratory categories.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Corolabs

Pulmonary Drug Delivery Devicescorolabs.com

Corolabs is a private Israeli company developing proprietary inhalation systems engineered to deliver medications directly to the alveoli for targeted pulmonary drug delivery.

What Corolabs does

Corolabs is a private, for-profit medical device / drug-delivery company headquartered in Migdal HaEmek, Israel. Per its firmographic description, the company develops proprietary inhalation systems specifically engineered to deliver medications to the alveoli — the deep gas-exchange regions of the lung — positioning it in the targeted pulmonary drug-delivery niche rather than conventional upper-airway or systemic inhalation therapy.

The company is founder-led: Asaf Weinberger is listed as Founder & CEO. No additional management, scientific advisors, board members, headcount, funding rounds, or strategic investors are disclosed in the available source material. There is no evidence of named customers, commercial products in market, partnership agreements, regulatory submissions, clinical milestones, patents, or certifications. The only verifiable public web presence captured in the input data is a listing on HugeDomains offering the corolabs.com domain for sale at $11,395, with that listing representing the domain registrar's commerce page rather than any corporate activity by Corolabs.

Because the source data contains no revenue, pricing, GTM, or product-portfolio detail, the company's current commercial stage cannot be reliably established. What can be stated with confidence is the company's stated technical focus (alveolar-targeted inhalation delivery), its jurisdiction (Israel), its founder identity, and its private, for-profit status. Any further inference on funding stage, burn rate, or runway would exceed the evidence available.

Corolabs firmographics

Firmographics
Name
Corolabs
Website
https://corolabs.com
Company type
Private
Operating status
Operating
Short description
Corolabs is a private Israeli company developing proprietary inhalation systems engineered to deliver medications directly to the alveoli for targeted pulmonary drug delivery.
Ownership category
akta.pro rank

Corolabs industry classification

Industry
Product category
Pulmonary Drug Delivery Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAJ
Nebulizers & Aerosol Drug Delivery Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

  • Inhaled drug delivery
  • Pulmonary therapeutics
  • Alveolar drug delivery
  • Inhalation medical devices
  • Respiratory drug delivery

Where Corolabs is headquartered

Location

Headquarters

HQ city
Migdal Hameq
HQ country
Israel
HQ region
Middle East

Markets served

Corolabs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goDomain purchase - full payment
OtherMonthlyDomain purchase - payment plan

Corolabs product offering

Product offering

Core offering

Corolabs specializes in proprietary inhalation systems specifically designed to deliver medications to the alveoli. The company's offering centers on a targeted pulmonary drug-delivery device platform intended for therapeutic use cases requiring deep-lung (alveolar) deposition of medication.

Product overview

The source data does not contain information about Corolabs's actual products or services. The page is from HugeDomains.com selling the domain name "CoroLabs.com" for $11,395. No product or service portfolio for Corolabs is described in this source.

Differentiator

Problem solved

Functional benefit

Products and services

  • Proprietary Inhalation System for Alveolar Drug Delivery

Companies that use Corolabs

Customer profile

Ideal customer profiles1 record

Corolabs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Corolabs partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

Corolabs competitors and assessment

Company assessment

Broad incumbents

  • United Therapeutics: Develops inhaled therapeutics such as Tyvaso DPI for pulmonary hypertension, operating device-plus-formulation inhaled programs analogous to where Corolabs' platform could be applied.
  • Omron Healthcare: Established manufacturer of consumer and clinical nebulizers; relevant comparable for the inhalation device category, though Corolabs' alveolar-targeting technology would be more specialized.
  • Vapotherm: Markets high-flow respiratory drug delivery systems; shares the respiratory drug-delivery category and serves overlapping hospital/clinical customers.
  • Philips Respironics: Large incumbent offering inhalation/nebulizer devices and ventilation solutions as part of a broader respiratory portfolio; overlaps with Corolabs on device-based drug delivery but covers a much wider product range.

Direct peers

  • PARI Medical (PARI GmbH): Specialist manufacturer of nebulizers and aerosol drug delivery systems for respiratory care, including devices engineered for deep-lung deposition — directly comparable to Corolabs' inhalation systems focus.
  • Aerogen: Developer of vibrating mesh nebulizer technology used in acute care and home settings to deliver drugs deep into the lungs; comparable as a device-only inhalation delivery company targeting alveolar deposition.

Emerging players

  • Insmed: Pursues inhaled formulations (e.g., ARIKAYCE) delivered to deep lung tissue using advanced nebulizer platforms — directly analogous alveolar-targeted strategy with a working drug-device combination.
  • Civitas Therapeutics (acquired by Acorda): Built an inhaled levodopa (ARCUS) platform targeting deep-lung delivery for Parkinson's; matches Corolabs' combination-product inhaled delivery thesis on a different therapeutic target.
  • Respira Therapeutics: Early-stage company working on inhaled therapeutics for pulmonary disease; relevant as a similarly sized emerging inhaled-drug-delivery peer in the same category.
  • Dance Biopharm: Developed a soft-mist inhaled insulin/biologics platform; comparable as a focused drug-device company pursuing deep-lung delivery rather than competing across broad respiratory categories.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights3 records

Customer concentration

Corolabs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Corolabs leadership team

Management profile

Number of profiles

Profiles1 record

Corolabs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Corolabs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corolabs

What does Corolabs do?

Corolabs specializes in proprietary inhalation systems specifically designed to deliver medications to the alveoli. The company's offering centers on a targeted pulmonary drug-delivery device platform intended for therapeutic use cases requiring deep-lung (alveolar) deposition of medication.

When was Corolabs founded?

Corolabs was founded in -1.

Where is Corolabs based?

Corolabs is headquartered in Migdal Hameq, Israel, in the Middle East region.

Who are Corolabs's main competitors?

Broad incumbents on record are United Therapeutics, Omron Healthcare, Vapotherm and Philips Respironics. Direct peers are PARI Medical (PARI GmbH) and Aerogen. Emerging players are Insmed, Civitas Therapeutics (acquired by Acorda), Respira Therapeutics and Dance Biopharm.

Does Corolabs have an API?

No public API is recorded for Corolabs.

What industry is Corolabs in?

Corolabs's product category is Pulmonary Drug Delivery Devices. Its primary akta.pro industry code is HLAHAIAJ, Nebulizers & Aerosol Drug Delivery Systems, with a secondary code of HLAHAGAE, Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales